Skip to Main Content

Paper Details

Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
Oncologist
6
2021
Advanced or Metastatic Renal Cell Carcinoma, Axitinib, Endoglin, Patients, TRC105, VEGF, VEGFR, antiendoglin monoclonal antibody, axitinib, carotuximab, mccRCC, metastatic clear cell renal cell carcinoma, patients, proliferating tumor vessels, renal, renal cell carcinoma, renal cell carcinoma (RCC) stem cells, tumor, vascular endothelial growth factor, vascular endothelial growth factor receptor
Author NameAffiliation
Toni K ChoueiriDana-Farber Cancer Institute
Russell K PachynskiWashington University School of Medicine
Kouros OwzarDuke University Medical Center
Primo N LaraUniversity of California, Davis Medical Center
Thai H HoMayo Clinic Arizona
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
  • 1 - 6

Datasets

Release 1.2